Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
Patents for C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
12/2008
12/04/2008WO2008145243A1 Pyridazinone derivatives
12/04/2008WO2008145242A1 Aryl ether pyridazinone derivatives
12/04/2008US20080300243 Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same
12/04/2008DE102007025718A1 Pyridazinonderivate Pyridazinone derivatives
12/04/2008CA2688518A1 Pyridazinone derivatives for use in the treatment of a disease which is influenced by inhibiton of met kinase
12/04/2008CA2688517A1 Aryl ether pyridazinone derivatives for use in the treatment of tumours
12/03/2008EP1996557A1 Pyridazinone compound and use thereof as herbicides
12/02/2008US7459564 thromboembolic and/or inflammatory disorders; 4-Aminomethyl-cyclohexanecarboxylic acid (1-biphenyl-3-yl-2-phenyl-ethyl)-amide; selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; improved pharmacological properties, plasma kallikrein activity
12/02/2008US7459558 Enzyme inhibitor on NO-synthase enzymes; treating STROKE, NEURODEGENERATIVE DISEASES, preventing ISCHEMIC OR HEMORRAGIC CARDIAC OR CEREBRAL INFARCTIONS; inhibiting lipidic peroxidation
12/02/2008US7459551 Method for preparing cyclic compounds
12/02/2008US7459453 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors
12/02/2008US7459414 Herbicides
11/2008
11/27/2008WO2008143706A2 Daa peripheral benzodiazepine receptor ligand for cancer imaging and treatment
11/27/2008WO2008011176A3 Myosin light chain kinase inhibitor compounds, compositions and related methods of use
11/27/2008WO2005025498A3 Substituted acetanilides and benzamides for the treatment of asthma and pulmonary inflammation
11/27/2008US20080293719 Pyridiazinone Derivatives for the Treatment of Tumours
11/26/2008EP1995240A1 Quinolone derivative or pharmaceutically acceptable salt thereof
11/26/2008EP1994005A1 Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
11/26/2008EP1506162B1 Synthesis of benzonitriles and benzimidates
11/26/2008CN100436418C N-Benzyl-3-indenylacetamides derivatives for treating neoplasia
11/25/2008US7456196 Alzheimer's disease; antihistamine; attention deficit disorder; hyperactivity; bipolar disorder; cognition activators; psychological disorder; anticancer agent; antidepressants; antiepileptic agents; gastrointestinal disorder; analgesics; 6-{2-[(2R)-2-methyl-1-pyrrolidinyl]ethyl}-2-(3-pyridinyl)quinoline
11/25/2008US7456195 Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
11/25/2008US7456180 Piperazine derivatives and their use as therapeutic agents
11/20/2008US20080287674 Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade
11/20/2008US20080287444 Pyrazole compounds useful as protein kinase inhibitors
11/20/2008US20080287434 New amino-alkyl-amide derivatives as CCR3 receptor ligands
11/19/2008EP1991531A1 Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors
11/19/2008EP1991530A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors
11/19/2008CN101309909A 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
11/19/2008CN101309902A Biphenyl derivatives and their use in treating hepatitis c
11/18/2008US7452911 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
11/18/2008US7452882 Thyroid hormone analogs
11/18/2008CA2278331C 3-heterocyclyl-substituted benzoyl derivatives
11/13/2008WO2008135413A1 Fungicidal pyridazines, method for the production thereof, and use thereof for controlling fungi and agents containing the same
11/13/2008WO2008135153A1 Novel polymorphic form of 2-(4-fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methyl-sulfonyl)phenyl]-3(2h)-pyridazinone (fhmp)
11/13/2008WO2008135152A1 Novel amorphous forms of 2-(4-fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methyl-sulfonyl)phenyl]-3(2h)-pyridazinone (fhmp)
11/13/2008WO2008114023A3 Phthalazinone derivatives
11/13/2008WO2008028168A3 Serine-threonine protein kinase and parp modulators
11/13/2008US20080280918 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease
11/13/2008US20080280915 {1-[6-(trifluoromethyl)pyridin-3-yl]methyl}(methyl)- lambda 4-sulfanylidenecyanamide; especially useful for the control of aphids and other sucking insects
11/13/2008US20080280911 Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4)
11/13/2008US20080280910 Phthalazinone derivatives
11/13/2008US20080280909 New phenylalanine derivatives
11/13/2008US20080280905 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
11/13/2008US20080280875 Fused phenyl amido heterocyclic compounds
11/13/2008DE102008000872A1 New pyrazine compounds useful in the fungicidal agent, for combating plant pathogenic fungus in protecting materials, plants, ground or seeds and to treat cancer
11/12/2008EP1893597B1 Ampa receptor potentiators
11/11/2008US7449464 4-{3-[4-(6-Chlorobenzothiazol-2-yl)-1,4-diazepan-1-ylcarbonyl]benzyl}-1(2H)-phthalazinone; Cancer, BRCA deficient
11/06/2008US20080275050 Pyridazine Compound and Use Thereof
11/06/2008DE102007020690A1 Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP) New amorphous form of 2- (4-fluorophenyl) -4-3-hydroxy-3-mehtyl-1-butoxy) -6 [4-methylsulfonyl) phenyl] -3 (2H) -pyridazinone (FHMP)
11/06/2008DE102007020689A1 Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP) Novel polymorph of 2- (4-fluorophenyl) -4-3-hydroxy-3-methyl-1-butoxy-5- [4-methylsulfonyl) phenyl] 3 / 2H) -pyridazinone (FHMP)
11/05/2008EP1987831A1 Compounds effecting glucokinase
11/05/2008CN100430373C Biological active compound of methoxy acrylic ester containing bis trifluoromethyl phenyl and preparing process thereof
10/2008
10/30/2008WO2008129029A1 Phthalazine and isoquinoline derivatives with slp receptor modulating activities
10/30/2008US20080269296 Diaryl ethers as opioid receptor antagonists
10/30/2008US20080269262 Therameutin Modulators
10/30/2008US20080269235 e.g. 5-Acetyl-4-[(3,5-difluorophenyl)amino]-2-ethyl-6-phenylpyridazin-3(2H)-one; Tumor Necrosis Factor alpha antagonist; antiinflammatory agent, autoimmune diseases; chronic obstructive pulmonary disease, rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease
10/30/2008CA2684965A1 Phthalazine and isoquinoline derivatives with s1p receptor modulating activities
10/29/2008CN101296912A Theramutein modulators
10/29/2008CN101296906A (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
10/29/2008CN101296892A PPAR active compounds
10/28/2008US7442794 Stereoisomers ; reacting with Lewis acid; purification
10/28/2008US7442793 Enzyme inhibitors as bactericides for infections and enzyme inhibitors
10/23/2008WO2008125627A1 Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonisis
10/23/2008US20080261994 4-[5-((1S,2R)-1-Carboxy-2-phenyl-cyclopropylsulfamoyl)-thiophen-2-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester; aggrecanase and matrix metalloproteinase (with zinc in the catalytic active center) inhibitor; antiarthritic agent: osteoarthritis, rheumatoid arthritis
10/23/2008US20080261947 Poly(ADP-ribose)polymerase inhibitor; ischemic diseases, cerebral infarction, antiretroviral, sensitizer for anticancer therapy, immunosuppressant; 5,6,7,8-tetrahydrophthalazin-1(2H)-one compounds; 2,3,4,6-tetrahydropyrido[2,3-d]pyridazin-5(1H)-one compounds
10/23/2008CA2681311A1 Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonisis
10/22/2008CN101291916A 9-aminocarbonylsubstituted derivatives of glycylcyclines
10/21/2008US7439242 PPARγ modulators
10/21/2008CA2174472C Arylalkylpyridazinones
10/16/2008WO2008024302A3 Compounds for treating proliferative disorders
10/16/2008US20080255152 Diaryl ethers as opioid receptor antagonists
10/16/2008US20080255128 e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis
10/15/2008EP1896416B1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
10/15/2008EP1660455B1 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
10/15/2008EP1476423B1 Arylsulfonamidobenzylic compounds
10/15/2008CN101287718A Substituted heteroaryl- and phenylsulfamoyl compounds
10/15/2008CN101284819A Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
10/14/2008US7435823 2,3-Dihydro-4H-1,4-benzoxazine derivatives containing an optionally fused pyridine or pyrimidine ring; 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-phenyl-2,3-dihydro-4H-1,4-benzoxazine-4-carboxamide; kinase inhibitors; inflammation, angiogenesis and cancer
10/09/2008WO2008062276A8 Acetylene derivatives as stearoyl coa desaturase inhibitors
10/09/2008WO2008057873A3 Inhibitors of hepatitis c virus
10/09/2008WO2008057871A3 Inhibitors of hepatitis c virus
10/07/2008US7432287 e.g. 3-(6-ethanesulfonylpyridin-3-yloxy)-5-(2-hydroxy-1-methyl-ethoxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide; glucokinase activator; antidiabetic agent; obesity, insulin resistance
10/07/2008US7432285 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
10/07/2008US7432263 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
10/07/2008US7432261 Improved pharmacokinetic properties, activity, oral bioavailability, potency, effective half-lives in vivo; fewer side effects; attaining high concentrations of phosphonate-containing molecules in target cells
10/02/2008US20080242655 Aza-indolyl compounds and methods of use
10/01/2008CN101274914A Asymmetric aromatic diamine having naphthalenone binaphthyl structure, preparation and use thereof
10/01/2008CN100422173C Substituted pyridines and pyridazines with angiogenesis inhibiting activity
10/01/2008CN100422172C Substituted pyridines and pyridazines with angiogenesis inhibiting activity
10/01/2008CN100422147C Method of preparing compound of 0-substituted sulphonyl propylhomoserin class
09/2008
09/30/2008US7429278 N-(2-Thiophen-2-ylethyl)benzene-1,4-diamine; hair dye; very strong and sparingly selective coloration of keratin fibers, light fast, avoiding the degradation of the fibers
09/30/2008CA2381001C Carbamate derivative and agricultural/horticultural fungicide
09/30/2008CA2303848C Substituted anilides
09/25/2008WO2008114023A2 Phthalazinone derivatives
09/25/2008WO2008047082A3 Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
09/25/2008US20080234301 Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases
09/25/2008US20080234278 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions
09/25/2008US20080234273 Such as 3-{[4-(azetidin-1-ylcarbonyl)-2-chlorophenyl]oxy}-5-({(1S)-2-[(difluoromethyl)oxy]-1-methylethyl}oxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide; glucokinases (Glk)
09/24/2008CN101273020A NNRT inhibitors
1 ... 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 ... 85